| Index | Health Authority | Therapy | Title | NCT# | Phase | For | US Contact | International Contact | Locations |
| 1 | United Kingdom: Medicines and Healthcare Products Regulatory Agency | AZD2171 | The Biological Activity of AZD2171 in GIST | NCT00385203 | II | GIST | AstraZeneca Cancer Support Network, 1-866-992-9276, | information.center@astrazeneca.com | The Royal Marsden NHS Foundation Trust in London and Christie Hospital NHS Trust in Manchester |
| 2 | FDA | Sutent | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | NCT00094029 | III | GIST | EmergingMed 1-800-620-6104 | EmergingMed 1-877-416-6248, sutent@emergingmed.com | Chile, Colombia, India, Turkey, Spain, Finland, Taiwan, Singapore, Rep. of Korea, Hong Kong |
| 3 | Finland: National Agency for Medicines | PKT787 | PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib | NCT00117299 | II | GIST | Heikki Joensuu, M.D., +358-9-471 73208, heikki.joensuu@hus.fi; Mia Viskari, +358-9-4711, mia.viskari@hus.fi | Helsinki University Central Hospital, Helsinki, FIN-00029, Finland | |
| 4 | FDA | BMS-354825 | A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors | NCT00099606 | I | Neoplasms | BMS Call Center, 1-866-892-1BMS Ext. 131; Boston, MA; Detroit, MI | BMS Call Center Outside the US & Canada, 941-906-4711 Ext. 131 | Glasgow, Strathclyd, United Kingdom |
| 5 | Japan: Ministry of Health, Labor and Welfare | BMS-354825 | A Phase I Study of BMS-354825 in Patients With Solid Tumors | NCT00339144 | I | Tumors | BMS Call Center, 1-866-892-1BMS Ext. 376 | BMS Call Center Outside the US and Canada, 1-941-906-4711 Ext. 376 | Toshima-Ku, Tokyo, Japan |
| 6 | Japan: Ministry of Health, Labor and Welfare | LBH589 | LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-Cell Lymphoma | NCT00412997 | I | Advanced Solid Tumors | Novartis +81-3-3797-8748 | Tokyo, Japan | |
| 7 | OSI-930 | A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients with Advanced Solid Tumors | I | Advanced Solid Tumors | Royal Marsden NHS Dr. Michelle Scurr, Principal Investigator | ||||